Oriel-M Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, formulated for the management of allergic conditions such as allergic rhinitis and chronic asthma. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 histamine receptors, thereby alleviating symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks the cysteinyl leukotriene receptor (CysLT1), reducing inflammation, bronchoconstriction, and mucus production associated with asthma and allergic rhinitis. The synergistic action of these agents provides comprehensive relief from both immediate and delayed allergic responses. Oriel-M is indicated for patients requiring concomitant treatment of allergic rhinitis and bronchial asthma or those inadequately controlled by monotherapy. It is generally well-tolerated, with a low incidence of adverse effects such as headache, fatigue, and gastrointestinal discomfort. Caution is advised in patients with hepatic impairment or a history of neuropsychiatric events. Oriel-M should be administered orally once daily, preferably in the evening, to optimize therapeutic outcomes. Regular monitoring and adherence to prescribed dosage are essential to ensure efficacy and minimize potential risks. This combination therapy offers an effective option for improving quality of life in patients with allergic respiratory disorders.